Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 20, Issue 1, 2008, Pages 106-115

  Nodin, N ^a   Carballo Dieguez A ^a   Ventuneac, A M ^a   Balan, I C ^a   Remien, R ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

ADULT; ANUS INTERCOURSE; ARTICLE; ATTITUDE TO CHANGE; ATTITUDE TO SEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SEMI STRUCTURED INTERVIEW;

ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; NEW YORK CITY; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES;

EID: 39349118095     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701449096     Document Type: Article

References (40)

1. Bartholow, B.N., MacQueen, K.M., Douglas, J.M., Buchbinder, S., McKirnan, D., & Judson, F.N. (1997). Assessment of the changing willingness to participate in Phase III HIV vaccine trials among men who have sex with men. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 16, 108-115.
2. Carballo-Diéguez, A., Dowsett, G., Ventuneac, A., Remien, R., Balan, I., Dolezal., C., et al. (2006). Cybercartography of popular Internet sites used by New York City MSM interested in bareback sex. AIDS and Education, 18, 475-489.
3. Carballo-Diéguez, A., & Bauermeister, J. (2004). 'Barebacking': Intentional condomless anal sex in HIV-risk contexts. Reasons for and against it. Journal of Homosexuality, 47, 1-16.
4. Carballo-Diéguez, A., Stein, Z., Saez, H., Dolezal, C., Nieves-Rosa, L., & Diaz, F. (2000). Frequent use of lubricants for anal sex among men who have sex with men: The HIV prevention potential of a microbicidal gel. American Journal of Public Health, 90, 1117-1121.
5. CDC (1994). Zidovudine for the prevention of HIV transmission from mother to infant. Morbidity and Mortality Weekly Report, 43, 285-287.
6. Clatts, M.C., Goldsamt, L.A., & Yi, H. (2005). An emerging HIV risk environment: A preliminary epidemiological profile of an MSM POZ Party in New York City. Sexually Transmitted Infections, 81, 373-376.
7. Cohen, J. (2006). Protect or disinhibit? New York Times Magazine, 22 January, 2006, p. 30.
8. Cohen, J. (1994). AIDS and journalism: Trying to tell too clear a story. Integration, 42, 21-22.
9. Cox, J., Beauchemin, J., & Allard, R. (2004). HIV status of sexual partners is more important than antiretroviral treatment related perceptions for risk taking by HIV positive MSM in Montreal, Canada. Sexually Transmitted Infections, 80, 518-523.
10. Crossley, M.L. (2004). Making sense of 'barebacking': Gay men's narratives, unsafe sex and the 'resistance habitus'. British Journal of Social Psychology, 43, 225-244.
11. Darroch, J.E., & Frost, J.J. (1999). Women's interest in vaginal microbicides. Family Planning Perspectives, 31, 16-23.
12. De Visser, R. (2004). Delayed application of condoms, withdrawal and negotiation of safer sex among heterosexual young adults. AIDS Care, 16, 315-322.
13. Esparza, J. (2005). The global HIV vaccine enterprise. International Microbiology, 8, 93-101.
14. Gross, M., Seage, G.R., Mayer, K.H., Goldstein, R.S., Losina, E., & Wold, C. (1996). Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 12, 406-412.
15. Halkitis, P.N., Wilton, L., Wolitski, R.J., Parsons, J.T., Hoff, C.C., & Bimbi, D.S. (2005). Barebacking identity among HIV-positive gay and bisexual men: Demographic, psychological and behavioral correlates. AIDS, 19, 27-35.
16. Hays, R.B., & Kegeles, S.M. (1999). Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 20, 164-171.
17. Jain, N., Yusuf, H., Wortley, P.M., Euler, G.L., Walton, S., & Stokley, S. (2004). Factors associated with receiving hepatitis B vaccination among high-risk adults in the US: An analysis of the National Health Interview Survey, 2000. Family Medicine, 36, 480-486.
18. Keller, S.N., & Brown, J.D. (2002). Media interventions to promote responsible sexual behavior. Journal of Sex Research, 39, 67-72.
19. Kinloch-de Loes, S. (2004). Role of therapeutic vaccines in the control of HIV-1. Journal of Antimicrobial Chemotherapy, 53, 562-566.
20. Koblin, B.A., Avrett, S., Taylor, P.E., & Stevens, C.E. (1997). Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 15, 165-171.
21. Koblin, B.A., Heagerty, P., Sheon, A., Buchbinder, S., Celum, C., Douglas, J.M., et al. (1998). Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the US. AIDS, 12, 785-793.
22. Kuo, I., Sherman, S.G., Thomas, D.L., & Strathdee, S.A. (2004). Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportunities to prevent infection. Drug and Alcohol Dependence, 73, 69-78.
23. Lange, J.M. (2005). We must not let protestors derail trials of pre-exposure prophylaxis for HIV. PLoS Medicine, 2, 248.
24. McOwan, A., Gilleece, Y., Chislett, L., & Mandalia, S. (2002). Can targeted HIV testing campaigns alter health-seeking behaviour? AIDS Care, 14, 385-390.
25. Mantell, J.E., Myer, L., Carballo-Diéguez, A., Stein, Z., Ramjee, G., Morar, N.S., et al. (2005). Microbicide acceptability research: Current approaches and future directions. Social Science and Medicine, 60, 319-330.
26. Martin, J.N., Roland, M.E., Neilands, T.B., Krone, M.R., Bamberger, J.D., Kohn, R.P., et al. (2004). Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS, 18, 787-792.
27. Marks, G., Mansergh, G., Crepaz, N., Murphy, S., Miller, L.C., & Appleby, P.R. (2000). Future HIV-prevention options for men who have sex with men: Intention to use a potential microbicide during anal intercourse. AIDS and Behavior, 4, 279-287.
28. Newman, P.A., Duan, N., Rudy, E.T., & Anton, P.A. (2004). Challenges for HIV vaccine dissemination and clinical trial recruitment: If we build it, will they come? AIDS Patient Care and STDs, 18, 691-701.
29. Newman, P.A., Duan, N., Lee, S.J., Rudy, E.T., Seiden, D.S., Kakinami, L., et al. (2006). HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine, 24, 2094-2101.
30. Ooi, C., Dayan, L., & Yee, L. (2004). Knowledge of post exposure prophylaxis (PEP) for HIV among general practitioners in northern Sydney. Sexually Transmitted Infections, 80, 420.
31. Parsons, J.T., Severino, J., Nanin, J., Punzalan, J.C., von Sternberg, K., Missildine, W., & Frost, D. (2006). Positive, negative, unknown: Assumptions of HIV status among HIV-positive men who have sex with men. AIDS Education and Prevention, 18, 139-149.
32. Pulerwitz, J., Amaro, H., De Jong, W., Gortmaker, S.L., & Rudd, R. (2002). Relationship power, condom use and HIV risk among women in the US. AIDS Care, 14, 789-800.
33. Roland, M.E., Neilands, T.B., Krone, M.R., Katz, M.H., Franses, K., Grant, R.M., et al. (2005). Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clinical Infections Diseases, 41, 1507-1513.
34. Schechter, M., do Lago, R.F., Mendelsohn, A.B., Moreira, R.I., Moulton, L.H., & Harrison, L.H. (2004). Behavioral impact, acceptability and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 35, 519-525.
35. Singh, J.A., & Mills, E.J. (2005). The abandoned trials of pre-exposure prophylaxis for HIV: What went wrong? PLoS Medicine, 2, 234.
36. Smith, M.J. (2002). Will vaginal microbicides be acceptable? Network, 22, 2.
37. Strauss, R.P., Sengupta, S., Kegeles, S., McLellan, E., Metzger, D., Eyre, S., Khanani, F., Emrick, C.B., & MacQueen, K.M. (2001). Willingness to Volunteer in Future Preventive HIV Vaccine Trials: Issues and Perspectives From Three U.S. Communities. J Acquir Immune Defic Syndr., 26(1), 63-71.
38. Varghese, G.M., Abraham, O.C., & Mathai, D. (2003). Post-exposure prophylaxis for blood borne viral infections in healthcare workers. Postgraduate Medical Journal, 79, 324-328.
39. Weeks, M.R., Mosack, K.E., Abbott, M., Sylla, L.N., Valdes, B., & Prince, M. (2004). Microbicide acceptability among high-risk urban US women: Experiences and perceptions of sexually transmitted HIV prevention. Sexually Transmitted Infections, 31, 682-690.
40. Wong, M.L., Lubek, I., Dy, B.C., Pen, S., Kros, S., & Chit, M. (2003). Social and behavioural factors associated with condom use among direct sex workers in Siem Reap, Cambodia. Sexually Transmitted Infections, 79, 163-165.